FDA Approves Johnson & Johnson’s Rybrevant for Lung Cancer Treatment
Lead: Johnson & Johnson's drug Rybrevant, in combination with chemotherapy, has been approved by federal regulators as a first-line...
non-small cell lung cancer
Merck’s Keytruda Receives CHMP Backing for Non-Small Cell Lung Cancer
**Lead:** Merck & Co. receives a recommendation to expand approval for its cancer drug Keytruda in certain non-small cell...
Foghorn Shares Rally as Eli Lilly Plans Clinical Program
Foghorn Therapeutics shares surged after announcing that Eli Lilly will conduct clinical trials for one of their cancer treatment...
Genprex Shares Surge on Positive Trial Progress
Genprex shares surged 15% after enrolling and dosing the first non-small cell lung cancer patient in a Phase 2...
ArriVent BioPharma to Sell 8.33 Million Shares in IPO
ArriVent BioPharma, a clinical-stage biopharmaceutical company, plans to raise approximately $135.7 million through its initial public offering. The company...
Verastem Oncology Receives FDA Fast-Track Designation for Lung Cancer Treatment
In a major development for the treatment of non-small cell lung cancer, Verastem Oncology has received fast-track designation from...
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application
Shares of Novocure surged 17% after the U.S. FDA accepted their pre-market application for a lung-cancer therapy. The Switzerland-based...
ArriVent BioPharma Files for IPO and Advances Lead Drug Candidate
ArriVent BioPharma, a clinical-stage biopharmaceutical company, has filed for an initial public offering and plans to list its stock...
Iovance Shares Plummet as FDA Halts Study After Patient Death
Shares of Iovance Biotherapeutics plunged in premarket trading after the FDA placed a clinical hold on a Phase 2...
Merck and Moderna Expand Phase 3 Study of Keytruda/V940 Combo
Merck and Moderna have announced the launch of a second late-stage study for their combination of cancer drug Keytruda...